Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of$ 0.47. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.51%. A quarter ago, it was expected that this immuno-oncology company would post a loss of$ 0.53 per share when it actually produced a loss of $0.37, delivering a surprise of 30.19%.Over the last four quarters, the ...